3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms by Site
3
Neoplasms
3
Neoplasms, Glandular and Epithelial
2
Neoplasms by Histologic Type
2
Digestive System Neoplasms
2
Digestive System Diseases
2
Colorectal Neoplasms
2
Thoracic Neoplasms
1
Stomach Neoplasms
1
Respiratory Tract Neoplasms
1
Rectal Diseases
1
Previously Treated Metastatic Colorectal Cancer
1
Pancreatic Neoplasms
1
Pancreatic Diseases
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Endocrine System Diseases
1
Endocrine Gland Neoplasms
1
Colonic Diseases
1
Carcinoma, Pancreatic Ductal
1
Carcinoma, Non-Small-Cell Lung
1
Bronchial Neoplasms
1
Adenocarcinoma
1
Interventions
Pemetrexed
3
Carboplatin
3
pembrolizumab
2
patritumab
1
osimertinib
1
napabucasin
1
camrelizumab
1
aflutinib
1
Vinorelbine
1
TNFSF10 protein, human
1
Paclitaxel
1
Injections
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Cisplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Bronchial Neoplasms
×
napabucasin
×
Clear all
NCT02826161
2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3
Terminated
4 enrolled
6 charts